Larson Financial Group LLC Trims Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Larson Financial Group LLC reduced its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 69.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 131 shares of the medical research company’s stock after selling 300 shares during the quarter. Larson Financial Group LLC’s holdings in IQVIA were worth $26,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in IQV. Impax Asset Management Group plc boosted its stake in shares of IQVIA by 9.7% during the 3rd quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock valued at $423,885,000 after buying an additional 157,809 shares during the last quarter. Assetmark Inc. boosted its stake in shares of IQVIA by 612.5% during the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after buying an additional 196 shares during the last quarter. Covestor Ltd boosted its stake in shares of IQVIA by 34.4% during the 3rd quarter. Covestor Ltd now owns 246 shares of the medical research company’s stock valued at $59,000 after buying an additional 63 shares during the last quarter. Ashton Thomas Securities LLC purchased a new position in shares of IQVIA during the 3rd quarter valued at approximately $57,000. Finally, Apollon Wealth Management LLC boosted its stake in shares of IQVIA by 9.6% during the 3rd quarter. Apollon Wealth Management LLC now owns 4,874 shares of the medical research company’s stock valued at $1,155,000 after buying an additional 427 shares during the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

IQV has been the topic of several research analyst reports. UBS Group reduced their price objective on IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Royal Bank of Canada restated an “outperform” rating and set a $270.00 price objective on shares of IQVIA in a research note on Monday, February 10th. JPMorgan Chase & Co. reduced their price objective on IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 18th. StockNews.com cut IQVIA from a “buy” rating to a “hold” rating in a research note on Wednesday. Finally, Barclays cut their target price on IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a research note on Monday, February 3rd. Five analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, IQVIA presently has an average rating of “Moderate Buy” and a consensus price target of $249.05.

IQVIA Price Performance

NYSE:IQV opened at $181.53 on Friday. The business’s 50-day moving average price is $196.87 and its 200 day moving average price is $211.38. The firm has a market cap of $32.01 billion, a P/E ratio of 24.20, a PEG ratio of 1.99 and a beta of 1.50. IQVIA Holdings Inc. has a 52-week low of $179.28 and a 52-week high of $256.76. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last released its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.